ezetimibe

AssetSmall moleculeAlso DP-R207, BR1017-2, Ezetimibe/Atorvastatin, Ezetimibe/Rosuvastatin

Inhibits ATP citrate lyase to reduce cholesterol biosynthesis

Stage: Approved
Modality: Small molecule
Target: AMPK signalling
Indications: 44
Trials: 247
Developers: 12

Indications

44

Heterozygous familial hypercholesterolemia
Approvedaccessdata.fda.gov7 Oct 2026
Homozygous familial hypercholesterolemia
Approvedaccessdata.fda.gov7 Oct 2026
Hyperlipidemia
Approvedaccessdata.fda.gov7 Oct 2026

41 more

Targets and what it contains6
Owner and partners12
Trials247
Evidence for its targets6
Competitors12
Aging relevance1
Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026 · 62 sources